Bellevue Group portfolio
Type not verifiedPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Bellevue Group reported a $4.8 bn portfolio of 148 positions to the SEC as of the end of Q2 2026. Its largest positions are AMGN, VRTX, ARGX.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Bellevue Group has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
What changed this quarter
134 positions with a change (10 new, 38 added to, 64 trimmed, 22 sold); also, 7 entered through an IPO, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAvalyn PharmaAVLN0.9% of the portfolio
- Newly listedSeaport TherapeuticsSPTX0.5% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Amgen+188%more sharesIncreased2.5% → 6.5%
- Insmed+13,787%more sharesIncreasedunder 0.1% → 3.1%
- Gilead Sciences+85%more sharesIncreased3.9% → 5.7%
- Krystal Biotech−84%fewer sharesReduced3.0% → 0.6%
- Oruka Therapeutics+227%more sharesIncreased0.6% → 3.3%
- United Therapeutics+8,976%more sharesIncreasedunder 0.1% → 2.1%
- Revolution Medicines−32%fewer sharesReduced3.6% → 4.1%
- BridgeBio Pharma+4,587%more sharesIncreasedunder 0.1% → 1.9%
- Regeneron Pharmaceuticals−44%fewer sharesReduced5.1% → 2.1%
- Alnylam Pharmaceuticals−99.5%fewer sharesReduced1.8% → under 0.1%
- Ionis Pharmaceuticals−47%fewer sharesReduced3.3% → 1.6%
- Scholar Rock Holding−32%fewer sharesReduced4.2% → 2.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- AmgenAMGN6.5%
- Vertex PharmaceuticalsVRTX6.0%
- ArgenxARGX5.9%
- Gilead SciencesGILD5.7%
- Revolution MedicinesRVMD4.1%
- Oruka TherapeuticsORKA3.3%
- InsmedINSM3.1%
- Scholar Rock HoldingSRRK2.8%
- Nuvalent2.7%
- Viridian TherapeuticsVRDN2.6%
- Relay TherapeuticsRLAY2.4%
- VaxcytePCVX2.4%
- United TherapeuticsUTHR2.1%
- Intuitive SurgicalISRG2.1%
- Regeneron PharmaceuticalsREGN2.1%
Portfolio by sector
- ● Health Care 100%
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Type not verified: we have not assigned a type because we found no document that is enough to tell. Most 13F filers are in this situation: we only review in depth those that meet the portfolio criteria.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Managers of a similar size
A 13F portfolio value between a third and three times this one, whatever the type of filer. It is not a comparison of what they hold.
- Stockbridge PartnersInvestment firm · $4.8 bn
- Smead Capital ManagementInvestment firm · $4.7 bn
- Sachem Head Capital ManagementInvestment firm · $4.8 bn
- MFN Partners ManagementInvestment firm · $4.8 bn
- Third PointInvestment firm · $4.6 bn
- Frazier Life Sciences ManagementInvestment firm · $4.6 bn